Scroll

nitrendipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1947	39562-70-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nitrendipine nitrendipin nitrepin	A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. Molecular weight: 360.37 Formula: C18H20N2O6 CLOGP: 3.73 LIPINSKI: 0 HAC: 8 HDO: 1 TPSA: 107.77 ALOGS: -4.41 ROTB: 7

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nitrendipine
nitrendipin
nitrepin

A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.

Molecular weight: 360.37
Formula: C18H20N2O6
CLOGP: 3.73
LIPINSKI: 0
HAC: 8
HDO: 1
TPSA: 107.77
ALOGS: -4.41
ROTB: 7

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.92 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	16.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	6.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	25 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1985	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	96.22	36.22	72	2404	201330	63285216
Fall	93.22	36.22	94	2382	392240	63094306
Antinuclear antibody negative	81.44	36.22	13	2463	221	63486325
Product prescribing error	79.33	36.22	32	2444	26257	63460289
Coombs positive haemolytic anaemia	75.46	36.22	13	2463	358	63486188
Herpes simplex reactivation	63.59	36.22	12	2464	556	63485990
Gastritis haemorrhagic	56.96	36.22	13	2463	1532	63485014
Antiphospholipid syndrome	55.05	36.22	13	2463	1777	63484769
Complex regional pain syndrome	51.50	36.22	13	2463	2344	63484202
Lymphopenia	47.42	36.22	20	2456	18307	63468239
Hypertensive angiopathy	45.97	36.22	7	2469	86	63486460
Anxiety disorder	44.53	36.22	13	2463	4037	63482509
Hyperlipidaemia	42.91	36.22	19	2457	19552	63466994
Hypertension	42.11	36.22	53	2423	279250	63207296
Premature baby	41.86	36.22	19	2457	20716	63465830
Bradycardia	38.90	36.22	28	2448	73199	63413347
Hypertensive crisis	37.28	36.22	16	2460	15270	63471276

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rectal prolapse	112.68	35.83	22	3427	470	34953012
Renal cyst haemorrhage	106.94	35.83	22	3427	617	34952865
Intraductal papillary mucinous neoplasm	98.86	35.83	20	3429	515	34952967
SARS-CoV-2 antibody test positive	85.21	35.83	17	3432	407	34953075
Carotid arteriosclerosis	83.58	35.83	22	3427	1836	34951646
Abdominal wall haemorrhage	82.75	35.83	17	3432	473	34953009
Vena cava injury	82.75	35.83	16	3433	324	34953158
Delayed graft function	79.69	35.83	22	3427	2199	34951283
Vascular anastomotic haemorrhage	72.90	35.83	14	3435	273	34953209
Mean cell volume increased	71.96	35.83	22	3427	3147	34950335
Spinal osteoarthritis	70.33	35.83	27	3422	7656	34945826
Aortic dilatation	69.83	35.83	18	3431	1383	34952099
Left ventricular hypertrophy	68.84	35.83	27	3422	8103	34945379
Perineal cyst	67.43	35.83	13	3436	259	34953223
Diverticulum intestinal	66.81	35.83	22	3427	3999	34949483
Product prescribing error	66.05	35.83	36	3413	22891	34930591
Hepatosplenomegaly	66.03	35.83	22	3427	4147	34949335
Renal artery stenosis	65.72	35.83	19	3430	2242	34951240
Actinic keratosis	64.06	35.83	22	3427	4545	34948937
Aortic arteriosclerosis	63.74	35.83	22	3427	4614	34948868
Vascular compression	63.23	35.83	13	3436	363	34953119
Hyperparathyroidism secondary	63.09	35.83	17	3432	1551	34951931
Dizziness	60.86	35.83	90	3359	218431	34735051
Spinal stenosis	57.25	35.83	21	3428	5248	34948234
Intervertebral disc space narrowing	54.75	35.83	14	3435	1041	34952441
Benign prostatic hyperplasia	53.85	35.83	27	3422	14468	34939014
Restless legs syndrome	51.15	35.83	22	3427	8332	34945150
Activated partial thromboplastin time prolonged	50.30	35.83	22	3427	8673	34944809
Syncope	50.14	35.83	53	3396	91398	34862084
Blood 25-hydroxycholecalciferol decreased	49.36	35.83	10	3439	259	34953223
Swelling of eyelid	49.22	35.83	13	3436	1098	34952384
Glycosylated haemoglobin increased	47.68	35.83	23	3426	11337	34942145
Vitamin D decreased	45.86	35.83	16	3433	3460	34950022
Squamous cell carcinoma of skin	45.58	35.83	22	3427	10859	34942623
Vertigo	44.48	35.83	29	3420	25507	34927975
Swelling	43.69	35.83	35	3414	42331	34911151
General physical health deterioration	43.25	35.83	58	3391	128211	34825271
Blood potassium increased	39.61	35.83	23	3426	16472	34937010
Haemorrhoids	39.51	35.83	22	3427	14553	34938929
Complications of transplanted kidney	37.93	35.83	15	3434	4594	34948888
Arteriosclerosis	37.82	35.83	20	3429	11948	34941534
Presyncope	36.54	35.83	23	3426	19036	34934446
Basal cell carcinoma	35.88	35.83	23	3426	19635	34933847

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product prescribing error	146.36	32.59	68	5374	44745	79694201
General physical health deterioration	137.53	32.59	128	5314	275110	79463836
Renal cyst haemorrhage	113.26	32.59	22	5420	670	79738276
Intraductal papillary mucinous neoplasm	98.21	32.59	20	5422	778	79738168
Dizziness	94.35	32.59	145	5297	526296	79212650
SARS-CoV-2 antibody test positive	90.86	32.59	17	5425	422	79738524
Syncope	88.54	32.59	83	5359	179366	79559580
Rectal prolapse	88.13	32.59	22	5420	2156	79736790
Vena cava injury	88.07	32.59	16	5426	336	79738610
Carotid arteriosclerosis	83.80	32.59	22	5420	2634	79736312
Abdominal wall haemorrhage	83.09	32.59	17	5425	677	79738269
Vascular anastomotic haemorrhage	78.05	32.59	14	5428	273	79738673
Delayed graft function	77.74	32.59	22	5420	3485	79735461
Perineal cyst	72.35	32.59	13	5429	256	79738690
Aortic dilatation	71.80	32.59	18	5424	1794	79737152
Bradycardia	71.27	32.59	65	5377	135492	79603454
Left ventricular hypertrophy	70.09	32.59	27	5415	11164	79727782
Benign prostatic hyperplasia	69.13	32.59	27	5415	11585	79727361
Actinic keratosis	65.95	32.59	22	5420	6020	79732926
Hepatosplenomegaly	65.85	32.59	22	5420	6047	79732899
Mean cell volume increased	65.21	32.59	22	5420	6231	79732715
Renal artery stenosis	64.52	32.59	19	5423	3463	79735483
Tongue biting	64.19	32.59	17	5425	2104	79736842
Vascular compression	62.52	32.59	13	5429	561	79738385
Hyperparathyroidism secondary	60.38	32.59	17	5425	2643	79736303
Diverticulum intestinal	58.34	32.59	22	5420	8583	79730363
Fall	57.78	32.59	112	5330	487517	79251429
Aortic arteriosclerosis	57.58	32.59	22	5420	8896	79730050
Complications of transplanted kidney	53.25	32.59	19	5423	6347	79732599
Spinal osteoarthritis	53.07	32.59	25	5417	16902	79722044
Intervertebral disc space narrowing	52.95	32.59	14	5428	1721	79737225
Blood 25-hydroxycholecalciferol decreased	49.35	32.59	10	5432	379	79738567
Squamous cell carcinoma of skin	47.95	32.59	22	5420	14011	79724935
Activated partial thromboplastin time prolonged	47.66	32.59	22	5420	14206	79724740
Glycosylated haemoglobin increased	44.19	32.59	23	5419	19237	79719709
Presyncope	44.00	32.59	30	5412	41024	79697922
Spinal stenosis	42.48	32.59	21	5421	15770	79723176
Hypertensive angiopathy	41.01	32.59	7	5435	101	79738845
Restless legs syndrome	40.47	32.59	22	5420	20070	79718876
Hypertension	39.06	32.59	76	5366	330916	79408030
Swelling of eyelid	38.13	32.59	13	5429	3798	79735148
Arteriosclerosis	36.83	32.59	20	5422	18207	79720739
Dysuria	36.05	32.59	29	5413	50922	79688024
Vitamin D decreased	35.61	32.59	16	5426	9709	79729237
Blood potassium increased	35.24	32.59	23	5419	29252	79709694
Postrenal failure	33.29	32.59	8	5434	669	79738277
Haemorrhoids	32.91	32.59	22	5420	29106	79709840

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA08	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
ATC	C09BB06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers
CHEBI has role	CHEBI:176497	geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.37	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-dependent L-type calcium channel subunit alpha-1D	Ion channel	Q01668	CAC1D_HUMAN	GATING INHIBITOR	IC50	8.40	IUPHAR	IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel	Q13936	CAC1C_HUMAN	BLOCKER	Ki	9.60	CHEMBL	SCIENTIFIC LITERATURE
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN	BLOCKER	IC50	7.60	IUPHAR
Voltage-dependent calcium channel gamma-1 subunit	Ion channel	Q06432	CCG1_HUMAN				WOMBAT-PK
Transthyretin	Secreted	P02766	TTHY_HUMAN		IC50	5.92	WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.68	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.52	DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		IC50	5.06	WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1F	Ion channel	O60840	CAC1F_HUMAN	GATING INHIBITOR	IC50	6	IUPHAR
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Enzyme	Q14123	PDE1C_HUMAN		IC50	5.73	CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	4.44	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	5.52	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.08	WOMBAT-PK
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	5.05	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	4.64	CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel		CAC1C_RAT	GATING INHIBITOR	IC50	6	IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1S	Ion channel		CAC1S_RAT	GATING INHIBITOR	IC50	6	IUPHAR
Platelet-activating factor receptor	GPCR		PTAFR_CAVPO		Ki	4.13	CHEMBL

External reference:

ID	Source
N0000167238	NUI
D00629	KEGG_DRUG
C0028127	UMLSCUI
CHEBI:7582	CHEBI
CHEMBL475534	ChEMBL_ID
CHEMBL251230	ChEMBL_ID
CHEMBL268609	ChEMBL_ID
DB01054	DRUGBANK_ID
D009568	MESH_DESCRIPTOR_UI
4507	PUBCHEM_CID
2334	IUPHAR_LIGAND_ID
4739	INN_ID
9B627AW319	UNII
7441	RXNORM
005383	NDDF
444757009	SNOMEDCT_US

Pharmaceutical products:

None